

Synthesis and regioselective transformations of ethoxy-substituted 5-(perfluoroalkyl)pyrimidines

Mohamed A. Ismail,^{a,b} Hanafi H. Zoorob,^b and Lucjan Strekowski^{a,*}

^a Department of Chemistry, Georgia State University, Atlanta, Georgia 30303, USA

^b Chemistry Department, Faculty of Science, Al-Mansoura University, Al-Mansoura, Egypt

E-mail: Lucjan@gsu.edu

(received 01 Jul 2002; accepted 29 Aug 2002; published on the web 06 Sep 2002)

Abstract

The reaction of 5-bromo-2,4-diethoxypyrimidine or 5-bromo-2-ethoxypyrimidine with a perfluoroalkyl iodide in the presence of Cu-bronze followed by acid hydrolysis of the resultant 5-perfluoroalkyl derivative furnishes the respective 5-perfluoroalkyluracil and 5-perfluoroalkylpyrimidin-2(1*H*)one. The treatment of the perfluoroalkyluracil with NaOH or sodium alkoxide gives the respective 5-(perfluoroacyl)- or 5-(1,1-dialkoxyperfluoroalkyl)-substituted uracil. 5-(Perfluoroalkyl)pyrimidine-2(1*H*)one is inert under these conditions.

Keywords: Pyrimidines, uracils, perfluoroalkylation, hydrolysis, regioselective transformations

Introduction

Fluorine-containing derivatives of pyrimidines including uracils and nucleosides are potent antitumor and antiviral agents.¹⁻⁴ Most previous synthetic work has focused on the preparation of 5-(trifluoromethyl)uracil and its nucleosides, and reports on the synthesis of higher perfluoroalkyl derivatives are scarce. The reported synthetic routes to such compounds are inefficient, require the use of specialized equipment and starting materials that are difficult to obtain, and/or utilize toxic reagents or solvents. These are perfluoroalkylation of uracil and uridine by the reaction of their bis(trimethylsilyl) derivatives with bis(perfluoroalkanoyl) peroxides,⁵ photochemically induced coupling by the reaction of uracil, its nucleosides or their expensive 5-iodo derivatives with toxic bis(perfluoroalkyl)mercury,⁶ the electrochemically induced coupling,^{7,8} and the highly inefficient reaction of uracil, its nucleosides or 5-iodouracil with a perfluoroalkyl iodide in the presence of copper bronze.^{9,10} The quite efficient reaction of 5-iodouracil nucleosides with trifluoromethylcopper requires an elaborate purification of the copper reagent but, in principle, could be extended to the preparation of higher perfluoroalkyl


analogs.¹¹ Unfortunately, this synthesis is not acceptable because the reaction, as reported, must be conducted in hexamethylphosphoramide which is a highly potent carcinogen.

Since 5-(perfluoroalkyl)uracils can be efficiently transformed into nucleosides,^{3,4} our work has been focused on finding a facile synthesis of the former compounds,¹² as described in this paper. We also report efficient chemical modifications of 5-(perfluoroalkyl)uracils that involve regioselectively the benzylic-type difluoromethylene moiety of the perfluoroalkyl substituent.

Results and Discussion


In contrast to the inefficient coupling reaction of a 5-halouracil with a perfluoroalkyl iodide, as mentioned above,^{9,10} the treatment of 5-bromo-2,4-diethoxypyrimidine (**1**) with perfluorobutyl iodide or perfluorohexyl iodide in the presence of activated copper bronze⁹ in DMSO gave the respective 5-(perfluoroalkyl)pyrimidines **2a,b** in high yields (Scheme 1). Acid-mediated hydrolysis of **2** furnished 5-(perfluoroalkyl)uracils **3**, also in high yields. Compounds **3a,b** are stable under acidic conditions but undergo an efficient hydrolysis by the reaction with hydroxide ion in aqueous solution to give the respective 5-(perfluoroacyl)uracils **6a,b**.

The suggested mechanism for **6** (Scheme 1) involves the intermediacy of **4** and **5** with a subsequent generation of similar derivatives and is consistent with the general pattern of the chemistry of the anionically activated perfluoroalkyl group in 2-perfluoroalkyl and 4-perfluoroalkyl-substituted anilines.¹³⁻¹⁶ A related mechanistic pathway has also been suggested for inhibition of thymidylate syntheses by 5-(trifluoromethyl)uracil which is used as an antitumor drug.¹⁷




Scheme 1. a: n = 4; **b:** n = 6.

Although perfluoroalkyl ketones, including **6**, resist the formation of sp^2 -type condensation products such as hydrazones, they readily undergo an addition reaction with a number of nucleophiles to form stable sp^3 -type adducts.¹⁸ A greatly simplified synthetic route to acetals **7-9** by the reaction of 5-(perfluoroalkyl)pyrimidines **3** with alkoxide ions is given in Scheme 2. Interesting features in the ^1H NMR spectra of these acetals are a broadened signal for *O*-methylene protons of the ethoxy derivatives **7** and a well-defined single AB absorption pattern for the *O*-methylene protons of the benzyloxy groups of **8**. As shown by decoupling experiments, these unusual absorption patterns are not due to a proton-fluorine coupling and, therefore, they must be a result of restricted rotation of the alkoxy groups around the central carbon atom of the acetal. In particular, the ^1H NMR spectra of **8** are consistent with the presence of a symmetric equilibrium conformation in which the pyrimidine plane bisects the acetal functionality. Due to symmetry, the two methylene moieties are equivalent but their geminal protons are not, thereby giving rise to a single AB system in the ^1H NMR spectrum, as observed. An interesting feature in the ^1H NMR spectrum of acetal **9** is a long-range coupling between C6-H of the uracil and two fluorine atoms of the perfluoroalkyl chain. This coupling gives rise to a doublet of doublets for C6-H at δ 7.56.



Scheme 2. **a:** $n = 3$; **b:** $n = 5$.

An extension of this work on the successful synthesis of 2-ethoxy-5-(perfluoroalkyl)pyrimidines **11a,b**, starting with 5-bromo-2-ethoxypyrimidine (**10**) and using a similar methodology, is given in Scheme 3. These products were efficiently hydrolyzed to give the expected 5-(perfluoroalkyl)pyrimidine-2(1*H*)ones **12a,b**. In contrast to the facile transformations of their uracil analogs **3**, as discussed above, compounds **12** are inert in the presence of base, even under forced conditions of an elevated temperature. For example, pyrimidinone **12a** was recovered in a virtually quantitative yield after its solution in aqueous sodium hydroxide had been heated in a pressure vessel to 120 °C for 4 h.



Scheme 3. a: $n = 4$; **b:** $n = 6$.

Experimental Section

General Procedures. Melting points (Pyrex capillary) are not corrected. 1H NMR (400 MHz) and ^{19}F NMR (282 MHz) spectra were recorded in $CDCl_3$ at 25 °C or $DMSO-d_6$ at 30 °C with TMS and C_6F_6 as the respective internal standards. Crude mixtures were analyzed, and EI mass spectra of pure components were obtained on a GC-MS instrument equipped with an on-column injector, a poly(dimethylsiloxane)-coated capillary column, and a mass selective detector operating at 70 eV.

2,4-Diethoxy-5-(perfluoroalkyl)pyrimidines 2a,b

5-Bromo-2,4-dichloro-pyrimidine was allowed to react with sodium ethoxide in ethanol as described previously¹⁹ and resultant 5-bromo-2,4-diethoxypyrimidine (**1**) was isolated by using the following simplified procedure. Thus, concentration of the mixture followed by extraction of **1** from the residue with ether/pentanes (3:1) and then concentration of the extract and cooling the residual solution resulted in crystallization of **1**: yield 92%, mp 69-70 °C (reported¹⁹ mp 69 °C).

A mixture of a perfluoroalkyl iodide (12 mmol), **1** (2.0 g, 8 mmol), Cu-bronze⁹ (1.7 g, 27 mmol), and anhydrous DMSO (8 mL) was stirred under a nitrogen atmosphere and heated to 110 °C for 20 h in a flask equipped with a dry-ice condenser. After cooling the mixture was poured into ether (200 mL) and filtered. The solution was washed with water (25 mL), dried ($MgSO_4$), and concentrated. Compounds **2** were obtained by flash chromatography on silica gel (30 g) by eluting with hexanes/AcOEt (19:1) followed by crystallization from ether/hexanes (2:1).

2,4-Diethoxy-5-(perfluorobutyl)pyrimidine (2a). Yield 72%; mp 35-36 °C; 1H NMR ($CDCl_3$) δ 1.42 (m, 6H), 4.48 (m, 4H), 8.40 (s, 1H); ^{19}F NMR ($CDCl_3$) δ 35.7 (2F), 39.2 (2F), 52.1 (2F),

80.8 (3F); EI-MS m/z 161 (100), 386 (10, M^+). *Analysis*. Calcd. for $C_{12}H_{11}F_9N_2O_2$: C, 37.32; H, 2.87; N, 7.25. Found: C, 37.56; H, 2.78; N, 7.16.

2,4-Diethoxy-5-(perfluorohexyl)pyrimidine (2b). Yield 80%; mp 50-51 °C; 1H NMR ($CDCl_3$) δ 1.42 (m, 6H), 4.47 (m, 4H), 8.40 (s, 1H); ^{19}F NMR ($CDCl_3$) δ 35.4 (2F), 38.8 (2F), 39.7 (2F), 40.0 (2F), 52.0 (2F), 80.3 (3F); EI-MS m/z 161 (100), 486 (20, M^+). *Analysis*. Calcd. for $C_{14}H_{11}F_{13}N_2O_2$: C, 34.58; H, 2.28; N, 5.76. Found: C, 34.42; H, 2.32; N, 5.68.

5-(Perfluoroalkyl)uracils 3a,b

A solution prepared from **2** (5 mmol), acetic acid (25 mL), and hydrochloric acid (2N, 5 ml) was heated under reflux for 1 h. Concentration under a reduced pressure followed by trituration of the crystalline residue with ether gave uracil **3**.

5-(Perfluorobutyl)uracil (3a). Yield 91%; mp 270-272 °C (reported⁹ mp > 250 °C); 1H NMR ($DMSO-d_6$) δ 8.00 (s, 1H), 11.6 (bs, exchangeable with D_2O , 2H); ^{19}F NMR ($DMSO-d_6$) δ 37.0 (2F), 41.0 (2F), 54.0 (2F), 82.0 (3F); EI-MS m/z 161 (100), 330 (10, M^+).

5-(Perfluorohexyl)uracil (3b). Yield 95%; mp 279-281 °C, decomp. (reported⁵ mp 277-278 °C, decomp.); 1H NMR ($DMSO-d_6$) δ 8.00 (s, 1H), 11.6 (bs, exchangeable with D_2O , 2H); ^{19}F NMR ($DMSO-d_6$) δ 37.0 (2F), 40.0 (2F), 41.0 (2F), 42.0 (2F), 54.1 (2F), 82.0 (3F); EI-MS m/z 161 (100), 430 (10, M^+).

5-(Perfluoroacyl)uracils 6a,b

A solution of **3** (1 mmol) in aqueous NaOH (0.2 M, 25 mL) was heated to 65 °C for 2 h, and then was acidified with hydrochloric acid (1 M) and extracted with ethyl acetate (3 x 25 mL). The extract was dried ($MgSO_4$) and concentrated, and the resultant solid was crystallized from EtOH (**6a**) or MeOH (**6b**).

5-(Perfluorobutanoyl)uracil (6a). Yield 87%; mp 274-278 °C, decomp.; 1H NMR ($DMSO-d_6$) δ 8.31 (s, 1H), 11.6 (bs, exchangeable with D_2O , 1H), 12.2 (bs, exchangeable with D_2O , 1H); ^{19}F NMR ($DMSO-d_6$) δ 38.4 (2F), 48.1 (2F), 82.8 (3F). *Analysis*. Calcd. for $C_8H_3F_7N_2O_3$: C, 31.19; H, 0.98; N, 9.09. Found: C, 31.35; H, 1.15; N, 8.84.

5-(Perfluorohexanoyl)uracil (6b). Yield 90%; mp 287-290 °C, decomp.; 1H NMR ($DMSO-d_6$) δ 8.31 (s, 1H), 11.6 (bs, exchangeable with D_2O , 1H), 12.2 (bs, exchangeable with D_2O , 1H); ^{19}F NMR ($DMSO-d_6$) δ 36.7 (2F), 41.0 (2F), 42.5 (2F), 48.6 (2F), 82.3 (3F). *Analysis*. Calcd. for $C_{10}H_3F_{11}N_2O_3$: C, 29.41; H, 0.74; N, 6.86. Found: C, 29.15; H, 0.99; N, 6.62.

Acetals 7a,b

A solution of **3** (1 mmol) in absolute EtOH (4 mL) was added under a nitrogen atmosphere to a solution of sodium ethoxide prepared from sodium (115 mg, 5 mmol) and absolute EtOH (5 mL). The mixture was heated under reflux for 8 h and then concentrated. Water (6 mL) was added to the residue and the solution was neutralized with Dowex cation exchange resin or hydrochloric acid (1 M) and concentrated. The product was crystallized from EtOH.

5-(1,1-Diethoxyperfluorobutyl)uracil (7a). Yield 79%; mp 242-243 °C; 1H NMR ($DMSO-d_6$) δ 1.16 (t, $J = 7$ Hz, 6H), 3.58 (m, 4H), 7.60 (s, 1H), 11.2 (bs, exchangeable with D_2O , 2H); ^{19}F

NMR (DMSO- d_6) δ 38.6 (2F), 46.0 (2F), 82.5 (3F); EI-MS m/z 139 (100), 383 (20, $M^+ + 1$). *Analysis*. Calcd. for $C_{12}H_{13}F_7N_2O_4$: C, 37.71; H, 3.43; N, 7.33. Found: C, 37.64; H, 3.47; N, 7.16.

5-(1,1-Diethoxyperfluorohexyl)uracil (7b). Yield 84%; mp 245-246 °C; 1H NMR (DMSO- d_6) δ 1.16 (t, $J = 7$ Hz, 6H), 3.56 (m, 4H), 7.56 (s, 1H), 11.2 (bs, exchangeable with D_2O , 2H); ^{19}F NMR (DMSO- d_6) δ 36.8 (2F), 40.5 (2F), 42.4 (2F), 46.7 (2F), 82.3 (3F); EI-MS m/z 139 (100), 483 (25, $M^+ + 1$). *Analysis*. Calcd. for $C_{14}H_{13}F_{11}N_2O_4$: C, 34.87; H, 2.72; N, 5.81. Found: C, 35.02; H, 2.76; N, 5.77.

Acetals 8a,b

Sodium benzyloxide prepared from sodium hydride (120 mg, 5 mmol) and benzyl alcohol (5 mL) was allowed to react with **3** (1 mmol) in benzyl alcohol (5 mL) and the mixture was worked up as described above. The product was crystallized from ether.

5-(1,1-Dibenzoyloxyperfluorobutyl)uracil (8a). Yield 66%; mp 225-227 °C; 1H NMR (DMSO- d_6) δ 4.63 (d, $J = 11.5$ Hz, 2H), 4.77 (d, $J = 11.5$ Hz, 2H), 7.36 (m, 10H), 7.65 (s, 1H), 11.3 (bs, exchangeable with D_2O , 2H); ^{19}F NMR (DMSO- d_6) δ 38.6 (2F), 46.4 (2F), 82.5 (3F); EI-MS m/z 308 (100), 507 (10, $M^+ + 1$). *Analysis*. Calcd. for $C_{22}H_{17}F_7N_2O_4$: C, 52.18; H, 3.38; N, 5.53. Found: C, 52.46; H, 3.33; N, 5.57.

5-(1,1-Dibenzoyloxyperfluorohexyl)uracil (8b). Yield 63%; mp 224-225 °C; 1H NMR (DMSO- d_6) δ 4.62 (d, $J = 11.5$ Hz, 2H), 4.76 (d, $J = 11.5$ Hz, 2H), 7.36 (m, 10H), 7.66 (s, 1H), 11.3 (bs, exchangeable with D_2O , 2H); ^{19}F NMR (DMSO- d_6) δ 36.9 (2F), 40.6 (2F), 42.5 (2F), 47.1 (2F), 82.3 (3F). *Analysis*. Calcd. for $C_{24}H_{17}F_{11}N_2O_4$: C, 47.54; H, 2.83; N, 4.62. Found: C, 47.69; H, 2.86; N, 4.64.

5-(2-Heptafluoropropyl-4-hydroxymethyl-1,3-dioxolan-2-yl)uracil (9). A mixture of glycerol (5 mL) and metallic sodium (0.115g, 5 mmol) was stirred at 23 °C until evolution of hydrogen ceased and then treated with a solution of **3a** (0.33g, 1 mmol). The mixture was heated to 150 °C for 8 h, concentrated by distillation of glycerol on a Kugelrohr, and the residue was dissolved in water (6 mL). The solution was neutralized with hydrochloric acid (1 M) and concentrated on a rotary evaporator to 4 mL. The resultant precipitate of **9** was filtered and crystallized from EtOH: yield 0.195g (51%); mp 273-274 °C; 1H NMR (DMSO- d_6) δ 3.50 (m, 2H), 3.80 (m, 1H), 4.24 (m, 2H), 5.01(bs, exchangeable with D_2O , 1H), 7.56(dd, $J_{H-F} = 29$ Hz, $J_{H-F} = 6$ Hz, 1H) 11.20 (bs, exchangeable with D_2O , 2H); ^{19}F NMR (DMSO- d_6) δ 38.2 (2F), 44.3 (2F), 82.2 (3F);); FAB-MS (thioglycerol) m/z 383 (100, $M^+ + 1$), 308 (60). *Analysis*. Calcd. for $C_{11}H_9F_7N_2O_5$: C, 34.56; H, 2.37; N, 7.32. Found: C, 34.76; H, 2.37; N, 7.25.

2-Ethoxy-5-(perfluoroalkyl)pyrimidines 11a,b

5-Bromopyrimidin-2(1H)one was obtained by the following modification of the published procedure.²⁰ Pyrimidin-2(1H)one hydrochloride (5.0 g, 38 mmol) was added gradually at 23 °C to a stirred solution of bromine (9.0 g, 56 mmol) in water (100 mL) and then the mixture was

stirred at 50 °C for 3 h. Concentration under a reduced pressure followed by crystallization of the residue from 95% EtOH gave 5-bromopyrimidin-2(1H)one: yield 88%, mp 233-235 °C (reported²⁰ yield 55%, mp 234-235 °C). Reaction of this product with POCl₃²¹ followed by the reaction of the resultant 5-bromo-2-chloropyrimidine with sodium ethoxide²² according to the published procedures furnished 5-bromo-2-ethoxypyrimidine (**10**). Compounds **11a,b** were synthesized by treatment of **10** with a perfluoroalkyl iodide in the presence of copper bronze as described above for **2** and purified by flash chromatography on silica gel (pentanes/ether, 4:1). Compound **11b** was crystallized from ether.

2-Ethoxy-5-(perfluorobutyl)pyrimidine (11a). Yield 64%; an oil; ¹H NMR (CDCl₃) δ 1.47 (t, J = 7 Hz, 3H), 4.53 (q, J = 7 Hz, 2H), 8.70 (s, 2H); ¹⁹F NMR (CDCl₃) δ 36.3 (2F), 39.0 (2F), 50.4 (2F), 80.8 (3F). EI-MS *m/z* 145 (100), 342 (25, M⁺). *Analysis*. Calcd. for C₁₀H₇F₉N₂O: C, 35.10; H, 2.06; N, 8.19. Found: C, 34.71; H, 2.00; N, 7.87.

2-Ethoxy-5-(perfluorohexyl)pyrimidine (11b). Yield 75%; mp 26-27 °C; ¹H NMR (CDCl₃) δ 1.47 (t, J = 7 Hz, 3H), 4.53 (q, J = 7 Hz, 2H), 8.70 (s, 2H); ¹⁹F NMR (CDCl₃) δ 35.8 (2F), 39.1 (2F), 39.9 (2F), 40.6 (2F), 50.7 (2F), 81.1 (3F). EI-MS *m/z* 145 (100), 442 (25, M⁺). *Analysis*. Calcd. for C₁₂H₇F₁₃N₂O: C, 32.60; H, 1.60; N, 6.34. Found: C, 32.57; H, 1.52; N, 6.23.

5-(Perfluoroalkyl)pyrimidin-2(1H)ones **12a,b**

Hydrolysis of **11** to give **12** was conducted by using the procedure for **6** described above.

5-(Perfluorobutyl)pyrimidin-2(1H)one (12a). Yield 84%; mp 205-206 °C; ¹H NMR (DMSO-*d*₆) δ 8.65 (s, 2H), 12.5 (bs, exchangeable with D₂O, 1H); ¹⁹F NMR (DMSO-*d*₆) δ 37.3 (2F), 40.1 (2F), 52.9 (2F), 82.1 (3F). EI-MS *m/z* 145 (100), 314 (30, M⁺). *Analysis*. Calcd. for C₈H₃F₉N₂O: C, 30.59; H, 0.96; N, 8.92. Found: C, 30.43; H, 1.06; N, 8.87.

5-(Perfluorohexyl)pyrimidin-2(1H)one (12b). Yield 93%; mp 209-211 °C; ¹H NMR (DMSO-*d*₆) δ 8.60 (s, 2H), 12.9 (bs, exchangeable with D₂O, 1H); ¹⁹F NMR (DMSO-*d*₆) δ 36.9 (2F), 40.2 (2F), 41.1 (2F), 41.5 (2F), 53.2 (2F), 82.3 (3F). EI-MS *m/z* 145 (100), 414 (20, M⁺). *Analysis*. Calcd. for C₁₀H₃F₁₃N₂O: C, 29.00; H, 0.73; N, 6.76. Found: C, 29.19; H, 0.67; N, 6.74.

Acknowledgments

This research was possible thanks to the financial assistance by the CHANNEL program of the government of Egypt and the Educational Aid Program of DuPont.

References

1. Curreri, A. R.; Ansfield, R. J.; McIver, F. H.; Waisman, H. A.; Hedelberger, C. *Cancer Res.* **1958**, *18*, 478.
2. Chaudhary, N. K.; Montag, B. J.; Heidelberger, C. *Cancer Res.* **1958**, *18*, 318.

3. De Clercq, E. Pyrimidine Nucleoside Analogues as Antiviral Agents; In *Targets for the Design of Antiviral Agents*; De Clercq, E.; Walker, R. T. Eds, Plenum: New York, 1984; pp 203-230.
4. Andres, P.; Marhold, A. *J. Fluorine Chem.* **1996**, *77*, 93; and references cited therein.
5. Nishida, M.; Fujii, S.; Kimoto, H.; Hayakawa, Y. *J. Fluorine Chem.* **1993**, *63*, 43.
6. Schwarz, B.; Cech, D.; Reefschläger, J. *J. Prakt. Chem.* **1984**, *326*, 985.
7. Médebielle, M.; Pinson, J.; Savéant, J. M. *Tetrahedron Lett.* **1992**, *33*, 7351.
8. Médebielle, M.; Oturan, M. A.; Pinson, J.; Savéant, J. M. *J. Org. Chem.* **1996**, *61*, 1331.
9. Cech, D.; Wohlfeil, R.; Etzold, G. *Nucleic Acids Res.* **1975**, *2*, 2183.
10. Cech, D.; Herrmann, G.; Staske, R.; Langen, P.; Preussel, B. *J. Prakt. Chem.* **1979**, *321*, 488.
11. Kobayashi, Y.; Yamamoto, K.; Asai, T.; Nakano, M.; Kumadaki, I. *J. Chem. Soc., Perkin Trans. 1*, **1980**, 2755.
12. Strekowski, L.; Ismail, M. A.; Zoorob, H. H. *Heterocycl. Commun.* **1998**, *4*, 399.
13. Strekowski, L.; Lin, S. Y.; Lee, H.; Wydra, R. L.; Kiselyov, A. S. *Heterocycl. Commun.* **1997**, *3*, 109.
14. Strekowski, L.; Lin, S. Y.; Lee, H.; Mason, J. C. *Tetrahedron Lett.* **1996**, *37*, 4655.
15. For a review, see: Kiselyov, A. S.; Strekowski, L. *Org. Prep. Proced. Int.* **1996**, *28*, 289.
16. For a review, see: Kobayashi, Y.; Kumadaki, I. *Acc. Chem. Res.* **1978**, *11*, 197.
17. Santi, D. V.; Sakai, T. T. *Biochemistry* **1971**, *10*, 3598.
18. Simmons, H. E.; Wiley, D. W. *J. Am. Chem. Soc.* **1960**, *82*, 2288.
19. Kumar, P.; Wiebe, L. *Nucleosides and Nucleotides* **1990**, *9*, 861.
20. Crosby, D.; Berthold, R. *J. Org. Chem.* **1960**, *25*, 1916.
21. Brown, D.; Lyall, J. *Aust. J. Chem.* **1964**, *17*, 794.
22. Brown, D.; Lee, T. *Aust. J. Chem.* **1968**, *21*, 243.